Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis

NCT06400511 is registered in ClinicalTrials.gov with Famy Life Sciences, a Viatris Company as lead sponsor.

NCT NCT06400511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06400511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis
Lead sponsor
Famy Life Sciences, a Viatris Company
Phase
Phase 3
Overall status
Terminated
Start date
April 22, 2024
Completion date
October 15, 2025
Enrollment
477 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

blepharitis